Table 2_Protein-free domains in native and ferroptosis-driven oxidized cell membranes: a molecular dynamics study of biophysical properties and doxorubicin uptake.docx by Yaser Shabanpour (13247160)

“…Using all-atom molecular dynamics simulations, we compared native red blood cell membranes (protein-free domains) with a ferroptosis model, in which PUFAs were replaced with hydroperoxide derivatives. …”

Table 1_Protein-free domains in native and ferroptosis-driven oxidized cell membranes: a molecular dynamics study of biophysical properties and doxorubicin uptake.pdf by Yaser Shabanpour (13247160)

“…Using all-atom molecular dynamics simulations, we compared native red blood cell membranes (protein-free domains) with a ferroptosis model, in which PUFAs were replaced with hydroperoxide derivatives. …”

Table 3_Protein-free domains in native and ferroptosis-driven oxidized cell membranes: a molecular dynamics study of biophysical properties and doxorubicin uptake.docx by Yaser Shabanpour (13247160)

“…Using all-atom molecular dynamics simulations, we compared native red blood cell membranes (protein-free domains) with a ferroptosis model, in which PUFAs were replaced with hydroperoxide derivatives. …”

Image 1_Protein-free domains in native and ferroptosis-driven oxidized cell membranes: a molecular dynamics study of biophysical properties and doxorubicin uptake.pdf by Yaser Shabanpour (13247160)

“…Using all-atom molecular dynamics simulations, we compared native red blood cell membranes (protein-free domains) with a ferroptosis model, in which PUFAs were replaced with hydroperoxide derivatives. …”

Table 1_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Table 4_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Table 3_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Table 2_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Table 5_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Table 6_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Data Sheet 2_Multi-omics analysis and evidence of IL1R1 as a potential biomarker for diabetes-associated intervertebral disc degeneration.pdf by Meng Yi (7853249)

“…Introduction<p>Low back pain (LBP), primarily driven by intervertebral disc degeneration (IDD), imposes a significant global health burden. While type 2 diabetes mellitus (T2DM) is a recognized risk factor for IDD, the shared molecular mechanisms remain incompletely characterized.…”

Data Sheet 1_Multi-omics analysis and evidence of IL1R1 as a potential biomarker for diabetes-associated intervertebral disc degeneration.pdf by Meng Yi (7853249)

“…Introduction<p>Low back pain (LBP), primarily driven by intervertebral disc degeneration (IDD), imposes a significant global health burden. While type 2 diabetes mellitus (T2DM) is a recognized risk factor for IDD, the shared molecular mechanisms remain incompletely characterized.…”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…</p>Objective<p>To evaluate feasibility and toxicity of plasma-cell targeting treatment using the subcutaneous anti-CD38 antibody daratumumab (Darzalex^®) in moderate to severe ME/CFS, and to assess the clinical course through 12–24 months follow-up after daratumumab intervention.</p>Methods<p>We performed a prospective, open-label pilot trial (EudraCT 2022–000281-18). …”

Image 2_The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients.tif by Kai Liu (159026)

“…Common comorbidities in the diabetic group were hypertension, cerebrovascular disease, chronic kidney disease and cardiovascular disease. We discovered that white blood cell count, neutrophil count, inflammatory marker levels, D-dimer, urea, precursor of the brain natriuretic peptide (Pro-BNP) increased and lymphocyte count, estimated glomerular filtration rate (eGFR), albumin decreased significantly in the diabetic group in laboratory test results. …”

Image 3_The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients.tif by Kai Liu (159026)

“…Common comorbidities in the diabetic group were hypertension, cerebrovascular disease, chronic kidney disease and cardiovascular disease. We discovered that white blood cell count, neutrophil count, inflammatory marker levels, D-dimer, urea, precursor of the brain natriuretic peptide (Pro-BNP) increased and lymphocyte count, estimated glomerular filtration rate (eGFR), albumin decreased significantly in the diabetic group in laboratory test results. …”

Image 1_The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients.tif by Kai Liu (159026)

“…Common comorbidities in the diabetic group were hypertension, cerebrovascular disease, chronic kidney disease and cardiovascular disease. We discovered that white blood cell count, neutrophil count, inflammatory marker levels, D-dimer, urea, precursor of the brain natriuretic peptide (Pro-BNP) increased and lymphocyte count, estimated glomerular filtration rate (eGFR), albumin decreased significantly in the diabetic group in laboratory test results. …”